Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

EU Conditional Approval Should Be A Drug Development Tool, Not A Rescue Remedy

This article was originally published in SRA

Executive Summary

Pharmaceutical companies in the EU should see conditional marketing authorization as a useful drug development planning tool, rather than as a "rescue option" to be used when they are unable to secure a full marketing authorization because they have not generated the required additional data, according to a senior European Commission official.

Advertisement

Related Content

Lilly’s Sarcoma Drug Lartruvo Latest To Test EU Conditional Approval System

Topics

Advertisement
UsernamePublicRestriction

Register